Skip to main content

TGen, Karmanos, U. of Michigan Partner on Komen-Funded Study

NEW YORK (GenomeWeb News) – The Susan G. Komen for the Cure foundation has granted $3.5 million to a trio of research institutes to study triple-negative breast cancer in African and African-American women.

Researchers at the Translational Genomics Research Institute, the Karmanos Cancer Institute in Detroit, and The University of Michigan Comprehensive Cancer Center will use the funding in a collaboration aimed at understanding why African and African-American women are at increased risk of this type of cancer and translating their discoveries into treatment

Breast cancer treatments generally are based on the presence of three specific biomarkers, but these are absent in patients with triple-negative breast cancer. The most successful treatments have targeted these markers, but these therapies don't work in triple-negative breast cancer patients.

Triple-negative breast cancer accounts for around 15 percent of diagnoses in Caucasian-American women, but 26 percent in African-American women and up to 82 percent in West-African women.

Other partners that will support the research include Baylor College of Medicine in Houston and the Van Andel Research Institute.

The researchers also will launch at least three clinical trials to study new treatments that would target cancer stem cells, and based on those results will undertake a larger clinical trial.

"Our goal is to unlock the clues as to why patients with triple-negative breast cancer so often fail to respond to available therapies, and to design new ways to more effectively treat this difficult form of cancer," Director of TGen's Integrated Cancer Genomics Division, John Carpten, said in a statement.

The researchers will study tumor cells from African and African-American women in search of molecular differences in triple-negative tumors, and then try to find out if targeting breast cancer stem cells has an impact on those tumors.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.